abs313.txt	background		some	but	not	all	epidemiologic	evidence	supports	a	role	forcholesterol	the	precursor	for	steroid	hormone	synthesis	in	prostate	cancer	using	pten-null	transgenic	mouse	model	of	we	tested	effectof	modifying	serum	cholesterol	levels	on	tumor	development	and	growth	hypothesized	that	reduction	would	lower	androgens	andslow	methods	ptenloxp/loxp-cre+	mice	consuming	ad	libitum	high	fat	cholesteroldiets	(40%	1	25%	cholesterol)	were	randomized	after	weaning	to	receive	thecholesterol	uptake	inhibitor	ezetimibe	(30	mg/kg/day)	or	no	intervention	andsacrificed	at	2	3	4	months	age	testosterone	weremeasured	by	elisa	intraprostatic	mass	spectrometry	prostatehistology	was	graded	proliferation	apoptosis	epithelium	andstroma	assessed	ki67	tunel	respectively	results	ezetimibe-treated	had	months(p	=	0	031)	positively	correlated	with	weight(p	033)	epithelial	(p	069)	negativelycorrelated	004)	wasunrelated	body	weight	195)	stromal	cell	wasreduced	group	010)	increased	4months	associated	elevated	dhea	andandrostenedione	043	p	074	031	respectively)	however	did	significantly	affect	adenocarcinoma	at2	(0	78	100%	vs	80	and100%	receiving	ezetimibe)	conclusions	though	therate	ofprostate	it	lowered	slowed	these	findings	support	promoting	cancergrowth	potentially	via	enhanced	androgen	signaling	may	provide	newinsight	into	cholesterol-lowering	interventions	treatment
